Compare AJANTA PHARMA with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA PFIZER AJANTA PHARMA/
PFIZER
 
P/E (TTM) x 24.7 42.4 58.3% View Chart
P/BV x 6.9 7.0 97.5% View Chart
Dividend Yield % 0.5 0.5 105.8%  

Financials

 AJANTA PHARMA   PFIZER
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
PFIZER
Mar-19
AJANTA PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,4223,840 37.0%   
Low Rs8982,080 43.2%   
Sales per share (Unadj.) Rs233.5455.0 51.3%  
Earnings per share (Unadj.) Rs44.093.8 46.9%  
Cash flow per share (Unadj.) Rs52.2109.4 47.7%  
Dividends per share (Unadj.) Rs9.0022.50 40.0%  
Dividend yield (eoy) %0.80.8 102.1%  
Book value per share (Unadj.) Rs255.1658.2 38.8%  
Shares outstanding (eoy) m88.0245.75 192.4%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.06.5 76.3%   
Avg P/E ratio x26.431.6 83.6%  
P/CF ratio (eoy) x22.227.1 82.2%  
Price / Book Value ratio x4.54.5 101.1%  
Dividend payout %20.524.0 85.3%   
Avg Mkt Cap Rs m102,081135,420 75.4%   
No. of employees `0006.82.6 258.5%   
Total wages/salary Rs m4,3073,238 133.0%   
Avg. sales/employee Rs Th3,022.67,911.4 38.2%   
Avg. wages/employee Rs Th633.41,230.9 51.5%   
Avg. net profit/employee Rs Th569.11,630.7 34.9%   
INCOME DATA
Net Sales Rs m20,55420,815 98.7%  
Other income Rs m2111,674 12.6%   
Total revenues Rs m20,76522,489 92.3%   
Gross profit Rs m5,6645,712 99.2%  
Depreciation Rs m721714 101.0%   
Interest Rs m1273 15.9%   
Profit before tax Rs m5,1436,599 77.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2732,309 55.1%   
Profit after tax Rs m3,8704,291 90.2%  
Gross profit margin %27.627.4 100.4%  
Effective tax rate %24.835.0 70.8%   
Net profit margin %18.820.6 91.3%  
BALANCE SHEET DATA
Current assets Rs m11,81227,167 43.5%   
Current liabilities Rs m3,7768,917 42.4%   
Net working cap to sales %39.187.7 44.6%  
Current ratio x3.13.0 102.7%  
Inventory Days Days7768 114.1%  
Debtors Days Days8230 271.1%  
Net fixed assets Rs m14,3988,862 162.5%   
Share capital Rs m175458 38.3%   
"Free" reserves Rs m22,27729,656 75.1%   
Net worth Rs m22,45230,113 74.6%   
Long term debt Rs m725 26.4%   
Total assets Rs m26,96239,400 68.4%  
Interest coverage x444.391.5 485.5%   
Debt to equity ratio x00 35.4%  
Sales to assets ratio x0.80.5 144.3%   
Return on assets %14.411.1 130.0%  
Return on equity %17.214.2 121.0%  
Return on capital %23.022.1 103.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,682428 2,494.0%   
Fx outflow Rs m2,102786 267.3%   
Net fx Rs m8,580-358 -2,395.9%   
CASH FLOW
From Operations Rs m3,748978 383.2%  
From Investments Rs m-2,228351 -634.4%  
From Financial Activity Rs m-1,475-1,099 134.2%  
Net Cashflow Rs m45231 19.6%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 1.6 7.5 20.7%  
FIIs % 7.6 4.9 155.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 23.7 71.7%  
Shareholders   20,968 85,207 24.6%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   STERLING BIOTECH  NOVARTIS  ALEMBIC PHARMA  ORCHID PHARMA  SANOFI INDIA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Mar 5, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS